17,261 trials
Focus of Study: Neural Correlates of Oxytocin Administration
Primary: Functional Magnetic Resonance Imaging (fMRI) Data: Change in BOLD Activity Between Placebo and Oxytocin Treatment. — 0.7944; 0.5790; 0.6119; 0.6688 BOLD signal change…
Cervical Squamous Cell Carcinoma · Recurrent Cervical Cancer
Primary: Progression-free Survival Greater Than 6 Months — 23.9 percentage of participants
Borderline Ovarian Serous Tumor · Low Grade Ovarian Serous Adenocarcinoma · Micropapillary Serous Carcinoma
Primary: Tumor Response — 15.4 percentage of patients
Leukemia, Lymphocytic, Acute
Primary: Complete Response (CR) Rate — 28 percentage of participants
Malignant Glioma
Primary: Effects of Low-dose Naltrexone Versus Placebo on Change in Quality of Life (QoL) in High-grade Glioma Patients Undergoing Standard Chemoradiation From Baseline — -3.73…
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
Cervical Adenocarcinoma · Cervical Squamous Cell Carcinoma · Stage IB Cervical Cancer
Primary: Overall Survival (OS) — 11 participants still alive after 2 years — p=.42
Liver Failure
Primary: Pharmacokinetics (Cmax and Cmin) of LCP-Tacro™ Compared to Prograf Early After Transplantations (Within the First 14 Days) in Adult de Novo Liver Transplant Recipients…
Pigmented Villonodular Synovitis · Diffuse-type Giant Cell Tumor · Tenosynovial Giant Cell Tumor
Primary: Percentage of Participants With Progression Free Survival — 82 percentage of participants with PFS
Adenomatous Polyp · Colorectal Cancer · Obesity
Primary: Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235) — 0.0228 weighted ratio of staining cells — p=> 0.773
Lipid Metabolism, Inborn Errors · Hyperlipidemias · Metabolic Diseases
Primary: Change From Baseline in Liver Triglyceride (TG) Content As Measured by Magnetic Resonance Spectroscopy (MRS) — 0.2; 1.2; 6.4; 0.8 percentage of total liver content…
Multiple Myeloma
Primary: Best Response — 56; 17; 10 participants
Asthma
Primary: Weekly Mean Combined Daytime Asthma Symptom Score — -0.456; -0.535; -0.504 units on a scale — p=0.4963
Ovarian Cancer
Primary: Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors…
Acral Lentiginous Malignant Melanoma · Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size
Primary: Objective Tumor Response (Partial or Complete Response) According to RECIST — 0 participants